Education
About Us
Working with TipRanks
Follow Us
Akari Therapeutics (AKTX)
NASDAQ:AKTX
AKTX Stock Chart & Stats
$0.53
-$0.09(-6.73%)
At close: 4:00 PM EST
$0.53
-$0.09(-6.73%)
Day’s Range― - ―
52-Week Range$0.46 - $2.45
Previous CloseN/A
Volume16.29K
Average Volume (3M)353.77K
Market Cap
$15.45M
Enterprise Value$35.60M
Total Cash (Recent Filing)$2.48M
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Apr 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding35,739,730
10 Day Avg. Volume136,951
30 Day Avg. Volume353,772
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap2.30
Enterprise Value/Revenue1.37K
Enterprise Value/Gross Profit2.74K
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$3.30Price Target Upside522.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Preclinical SuccessAkari announced preclinical data demonstrating activity of its antibody drug conjugate (ADC) novel payload PH1 in prostate cancer, particularly in the presence of AR-V7.
Product DevelopmentAkari Therapeutics has shifted the main focus of the company towards developing a novel and unique antibody-drug conjugate (ADC) platform.
Strategic PartnershipsThe departure from toxin-based payloads, along with validated targets, could make the Akari pipeline attractive for potential partners.
Bears Say
Financial StabilityThe company's weak balance sheet may present a significant risk.
Funding ChallengesThe financial overhang may weigh on the stock until the company is able to secure additional funds.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $0.46 and its highest was $2.45 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $15.45M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Apr 07, 2026 which is in 138 days.
How were Akari Therapeutics’s earnings last quarter?
Akari Therapeutics released its earnings results on Sep 25, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.03.
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 35,739,730 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Akari Therapeutics reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 0.901%.
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
Company Description
Akari Therapeutics
Akari Therapeutics Plc is a biopharmaceutical company focused on developing innovative treatments for rare and orphan diseases, particularly those involving severe inflammatory and allergic conditions. The company operates in the biotechnology sector, with its core products centered around inhibitors of the complement and leukotriene systems, which play a crucial role in the body's immune response.
AKTX Stock 12 Month Forecast
Average Price Target
$3.30
▲(522.64% Upside)
Technical Analysis
Sonnet BioTherapeutics Holdings
―
NanoViricides
―
Moleculin Biotech
―
Passage Bio
―
SAB Biotherapeutics
―
Ownership Overview
32.88% Insiders
0.63% Other Institutional Investors
66.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---